Received May 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 4N222 | IM |
A 47 years old male patient received Priorix IM instead of subcutaneous; A 47 years old male patient received Priorix; This non-serious case was reported by a consumer via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 47-year-old male patient who received MMR (Priorix) (batch number 4N222, expiry date 13-SEP-2026) for prophylaxis. On 23-APR-2025, the patient received Priorix (intramuscular, unknown deltoid). On 23-APR-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: A 47 years old male patient received Priorix IM instead of subcutaneous) and inappropriate age at vaccine administration (Verbatim: A 47 years old male patient received Priorix). The outcome of the subcutaneous injection formulation administered by other route and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 05-MAY-2025 On 23rd April 2025, a 47 year old male received Priorix intramuscularly in the deltoid instead of subcutaneously, which led to Subcutaneous injection formulation administered by other route and Inappropriate age at vaccine administration. The patient/reporter was not certain if he had received prior MMR injections in the past as a child, though he assumed that he had. However, since he was preparing for international travel, it was recommended that he receive a Priorix dose before his departure.